rabeprazole + colloidal bismuth pectin + tetracycline + furazolidone

This salvage treatment is a 14-day bismuth-based quadruple therapy (BQT) regimen specifically evaluated by Shandong University for the eradication of *Helicobacter pylori* in patients who have failed previous treatment attempts. The combination consists of rabeprazole (a proton pump inhibitor), colloidal bismuth pectin (a mucosal protective and bactericidal agent), and two antibiotics: tetracycline and furazolidone. Rabeprazole functions by inhibiting the H+/K+ ATPase pump in gastric parietal cells, thereby increasing gastric pH and improving the stability and efficacy of the co-administered antibiotics. Colloidal bismuth pectin exerts direct antimicrobial activity against *H. pylori* and provides a protective coating for the gastric mucosa. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while furazolidone, a nitrofuran antibiotic, interferes with bacterial oxidative enzyme systems and causes DNA damage. This regimen is particularly relevant in clinical settings where resistance to common antibiotics like clarithromycin and metronidazole is prevalent.

Other names

salvage treatment for failed eradication-Shandong University-Helicobacter pylori infectionsalvage treatment for failed eradicationbismuth-based quadruple therapyBQT